Announcements - OBI Pharma 台灣浩鼎

2024.Nov.05

Announcement of calls on unpaid shares of 2024 cash capital increase

2024.Nov.04

Announcement of the Consolidated Financial Statements for the third quarter of 2024 were approved by the Board of Directors.

2024.Oct.24

Announcement of the Company’s board meeting date to approve 2024Q3 consolidated financial report

2024.Oct.07

Announcement of issue price and banks designated to collect and deposit the proceeds for 2024 cash capital increase

2024.Sep.25

Announcement on behalf of OBIGEN of the Board’s resolution to lift the non-competition restrictions for CEO

2024.Sep.24

Announcement of reference date of cash capital increase and share subscription

2024.Aug.07

OBI receives US FDA Orphan Drug Designation for OBI-992 TROP2 ADC for the treatment of gastric cancer

2024.Aug.02

Announcement of change of accounting officer

2024.Aug.02

Announcement of change of acting spokesperson

2024.Aug.02

Announcement of new appointment of Chief Operating Officer

News

Latest News

Events

Latest events